MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- WOCKHARDT LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
Wockhardt Quarterly Results (WOCK)
Here are the latest quarterly results of Wockhardt. For more details, see the Wockhardt financial fact sheet and Wockhardt share price and chart. For a sector overview, read our pharmaceuticals sector report.
Wockhardt Quarterly Results
| No. of Mths Qtr. Ending |
3
Jun-18* |
3
Sep-18* |
3
Dec-18* |
3
Mar-19* |
3
Jun-19* |
3
Sep-19* |
3
Dec-19* |
3
Mar-20* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 10,077 | 11,257 | 10,459 | 9,791 | 8,631 | 8,022 | 8,692 | 6,869 | |
| Other income | Rs m | 74 | 61 | 21 | 54 | 81 | -2 | 172 | 137 | |
| Turnover | Rs m | 10,151 | 11,318 | 10,479 | 9,846 | 8,712 | 8,020 | 8,864 | 7,007 | |
| Expenses | Rs m | 10,033 | 10,583 | 10,637 | 9,236 | 8,232 | 7,545 | 7,350 | 6,735 | |
| Gross profit | Rs m | 133 | 755 | -178 | 556 | 399 | 477 | 1,342 | 135 | |
| Depreciation | Rs m | 392 | 402 | 412 | 454 | 550 | 534 | 563 | 609 | |
| Interest | Rs m | 727 | 651 | 636 | 635 | 709 | 646 | 787 | 614 | |
| Profit before tax | Rs m | -911 | -237 | -1,206 | -480 | -779 | -706 | 164 | -951 | |
| Tax | Rs m | -49 | -10 | -437 | -341 | -410 | 237 | -28 | -1,439 | |
| Profit after tax | Rs m | -862 | -228 | -769 | -139 | -369 | -942 | 192 | 487 | |
| Gross profit margin | % | 1.3 | 6.7 | -1.7 | 5.7 | 4.6 | 5.9 | 15.4 | 2.0 | |
| Effective tax rate | % | 5.4 | 4.0 | 36.3 | 71.0 | 52.6 | -33.6 | -17.0 | 151.2 | |
| Net profit margin | % | -8.6 | -2.0 | -7.3 | -1.4 | -4.3 | -11.7 | 2.2 | 7.1 | |
| Diluted EPS | Rs | -7.8 | -2.1 | -7.0 | -1.3 | -3.4 | -8.6 | 1.7 | 4.4 | |
| Diluted EPS (TTM) | Rs | -26.2 | -27.5 | -30.6 | -18.1 | -13.7 | -20.2 | -11.4 | -5.7 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: Wockhardt 3QFY20 Result Performance Review
More Pharmaceuticals Company Quarterly Results: J.B.CHEMICALS GSK PHARMA CIPLA PANACEA BIOTECH GLENMARK PHARMA
Compare WOCKHARDT With: J.B.CHEMICALS GSK PHARMA CIPLA PANACEA BIOTECH GLENMARK PHARMA
Compare WOCKHARDT With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Today's Market
Sensex Ends 260 Points Lower; Finance and Banking Stocks Witness Huge Selling(Closing)
Indian share markets witnessed negative trading activity today and ended their trading session lower.
Views on news
WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)
Jan 28, 2020 | Updated on Jan 28, 2020For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.
WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)
Aug 28, 2019 | Updated on Aug 28, 2019For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.
More Views on NewsMost Popular
Protect Your Wealth from Fund Managers (Fast Profits Daily)
May 14, 2020Do you know how much you are paying in fees to your mutual fund? In this video I'll share with you my views.
Covid-19 Offers a Rare Opportunity to Own This Brand Leader (Profit Hunter)
May 12, 2020Covid-19 has compounded uncertainties in investing but this smallcap company is strong enough to survive and even emerge stronger.
Of India's 20 Trillion Stimulus Package and the Swoosh Index for a Swoosh Recovery (Profit Hunter)
May 13, 2020For India's rapid economic recovery, hopping on to the Swoosh index is a must.
How Commodity Prices Tell You When Stocks Will Go Up (Fast Profits Daily)
May 20, 2020Commodity prices often provide clues to big moves in stock markets. In today's video, I'll explain this link.
Why Buffet - and you - should study Quantum Liquid Fund (The Honest Truth)
May 14, 2020Ajit Dayal on how Quantum Liquid Fund and Warren Buffett have similar investing styles.
MoreOUR TOP 5 IDEAS
- How to Trade the Coronavirus Crash - Download this FREE Report Now
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
WOCKHARDT SHARE PRICE
May 22, 2020 (Close)
TRACK WOCKHARDT
- Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON WOCKHARDT
WOCKHARDT 5-YR ANALYSIS
COMPARE WOCKHARDT WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.